Mr Mark Chadwick

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials, reducing the need for animal experiments. This optimisation also improves the efficacy of combinations in pre-clinical xenografts.

The company is also developing:

(i) Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials.

(ii) Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process.

(iii) Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects.

Physiomics has worked with Eli Lilly since 2007 and recently added a further two large pharmaceutical clients. In addition, Physiomics has collaborated with a number of other companies including Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies and Cyclacel. Fee-for-service, licensing and revenue sharing options are available.

Company Type
LinkedIn logo

Dr Bernard Chan United Kingdom

Competitive Drug Development International is an international biotechnology and pharmaceutical consulting company. Unlike a traditional consultancy who talk and advise, our mode of working is hands-on and delivery focused, in addition to the strategic planning. From evidence based protocol feasibility, to management of CROs and CMOs, to delivery of POC, we can achieve your specific objectives quickly and more cost-effectively. Come and see us at Bio-Europe 2012 in Hamburg at booth #27.

Dr Bernard Chan
LinkedIn logo Managing Partner 

Ms Karen Chandler-Smith

Come and see us at booth #73

BIA (UK BioIndustry Association)
LinkedIn logo Director of Business Development and Membership Services 

Mr Paul Cronin

Diamond Pharma Services is a leading technical and scientific consulting group of companies serving the biotechnology and pharmaceutical industry. Our emphasis is on the following areas:

•    Regulatory Affairs: From Product Concept to Registration and Beyond
•    Product Development: Nonclinical, CMC and Clinical Aspects
•    Pharmacovigilance: Clinical trial (Phase I-IV), Post-Marketing and QPPV Services
•    Compliance: GLP, GMP, GCP and QP Services

Our clients range from virtual start-up companies to the largest multi-national corporations. Our expertise includes products of recombinant DNA and hybridoma technology, nucleotide based products (RNA and DNA), synthetic peptides, chemical entities (innovative and generic), vaccines (therapeutic and prophylactic), blood products and advanced therapy medicinal products (gene and cell therapy products).

We have sophisticated and well-equipped office facilities and a state-of-the-art IT system. Our IT system includes a fully validated in-house eCTD system (Extedo) and safety database (ARISg). The company was founded in 2005 by Dr. Maureen Graham, formerly Director of Regulatory Affairs at Amgen. Our specialised team of more than 27 professionals includes those with a broad and varied industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.  

Contact details:

Paul Cronin
Director of Business Development
Diamond Pharma Services Limited
No 4 East Wing, Gemini House
Flex Meadow, Harlow
Essex, CM19 5TJ
United Kingdom
Tel:     +44 (0)1279 441616
Fax:     +44 (0)1279 418964

Come and see us at booth #73

Diamond Pharma Services Ltd
LinkedIn logo

Dr Lyn Daintree

CrystecPharma applies the latest supercritical fluid technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Crystec supercritical fluid technologies can be applied to both small drug molecules and biotechnologically sourced drugs.

Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.

Come and see us at booth #73

Company Type
LinkedIn logo

Mr Philip Diamond United Kingdom

Almac provides a comprehensive range of integrated services from research through to commercialisation.  Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.   

Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:

Biomarker Discovery & Development:
·         Companion Diagnostic Development
·         Genomic Services
·         Bioinformatics Consultancy
·         Proprietary Discovery Arrays

API Services & Chemical Development:
·         API Development & Manufacture
·         Peptide & Protein Technology
·         Accelerated First in Man Solution
·         Solid State Services
·         Isotope Chemistry
·         Biocatalysis
Pharmaceutical Development:
·         Preformulation & Early Stage Development
·         Scale Up and Late Stage Development
·         Clinical Trial Manufacture
·         Contained Development & Manufacture

Analytical Services:
·         Physical & Chemical Characterisation
·         Method Development & Validation
·         API & Drug Product Testing
·         Stability Testing

Clinical Trial Supply:
·         Comparator Blinding
·         Packaging & Labelling
·         QP Release
·         Global Distribution & Supply Chain Management

Clinical Technologies:
·         IVR / Web
·         ePRO
·         Statistical Services

Commercial Services
·         Manufacturing & Packaging
·         Product Launch & Distribution

Come and see us at booth #70

Company Type
Almac Group

Dr Josiah Dungwa

Pathology Diagnostics Ltd. based in Cambridge UK, is a leading industry accredited research organisation providing tissue laboratory and diagnostic services to international pharmaceutical, biotechnology and companion diagnostics clients. We provided centralized integrated drug and biomarker testing on human and rodent tissues including IHC assay validation, digital whole slide scanning and fully automated quantitative image analysis enabling faster higher quality results at a fraction of the cost of traditional pathology approaches. We have a proven track record in early discovery & preclinical studies, clinical trials, biomarker and companion diagnostic R&D enabling you to make objective data driven decisions on your studies. Our team consists of on-site and remote medical and veterinary pathologists plus research scientists with several decades’ pathology and research experience. We hold full industry accreditation so that you may be assured that the results we generate are accurate consistent and reliable.

At Pathology Diagnostics Ltd we are embracing developments in digital pathology to become a leading reference laboratory for biomarker testing for personalized medicine. Over the last few years we have e valuated over 130 biomarkers in > 75,000 patient samples from a wide variety of tumour and normal tissues in oncology, cardiovascular, metabolic, neurodegenerative & respiratory disease.

Come and visit us at booth 73.

Pathology Diagnostics

Mr Peter Farmer

Molecular Profiles provides contract development and manufacturing services for clients globally. We specialise in early development and clinical trial manufacturing up to phase IIb and have expertise in understanding and formulating drug candidates that possess challenging characteristics. Our experience and capabilities provide the following product outputs; solid oral dosage forms for immediate and modified release, topicals, liquids and DPI products, we also utilise Xcelodose precision dosing for rapid development of low dose clinical trial supplies. Our facilities can handle potent candidates and controlled drug substances.

We utilise the most appropriate formulation strategy for your drug candidate based around your quality target product profile. For example in the formulation development of poorly water soluble / bioavailable candidates this may include our expertise in nanomilling, spray drying, SEDDS, SMEDDS and other absorption enhancing approaches.

Underpinning all of our development and manufacturing expertise is a wealth of experience in materials characterisation and analysis which has been utilised to solve some of the most complex challenges in API and formulation development. Our renowned problem to solution approach has been utilised on over a 1000 development projects and also in establishing the patent position for commercialised blockbuster products.

Company Type
Molecular Profiles
LinkedIn logo

Ms Angelina Fisher United Kingdom

Founded in 2002, Advocates Ltd., Pharmaceutical & Healthcare is a global Contract Development Services Organisation (CDSO), based in Hong Kong, USA and Scotland.

Advocates Pharmaceutical & Healthcare
LinkedIn logo

Ms Julie Foster

Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses.

The Contract Research Division delivers innovative preclinical research services in the areas of oncology, mucositis, inflammation, wound healing and skincare.

Highlights include 1st in class services in:

Oncology: We have a particular focus in developing preclinical in vivo models of Oncology that are clinically relevant. Some of these include novel models of Leukemia, orthotopic colon, orthotopic lung, orthotopic breast, and novel models of prostate cancer.

Inflammation: We are highly experienced in the field of Inflammatory bowel disease (IBD) and offer 3 preclinical models of the disease: Adoptive T-cell transfer (chronic), DSS (acute) and TNBS (acute). We are also now offering in vitro inflammation assays, and are developing in vivo models of RA.

Mucositis: World renowned experience in Oral and Intestinal Mucositis. Epistem can progress a potential therapeutic candidate through mechanism of action studies, dose optimisation and scheduling, to functional efficacy studies.

Plucked Hair Biomarker Platform: Patient plucked hair is an ideal surrogate tissue that can be used to measure direct response to drug treatment for biomarker studies. Epistem has developed an innovative, non-invasive plucked hair biomarker platform that enables measurment of target changes in response to drug (including phosphorylated proteins) within a single plucked human hair.

Come and see us at booth #73

Company Type
LinkedIn logo Business Development Manager Europe